Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 75%
filed 2026-06-18
Item 7.01
Enanta announced advancement of zelicapavir into a registrational Phase 2b/3 clinical trial following a successful End-of-Phase 2 FDA meeting, plus initiation of a pediatric Phase 2b trial, both with topline data expected in 2027. This represents material clinical development progress for a lead program in a clinical-stage biotech company, but does not fit neatly into the standard 8-K event taxonomy (not an earnings release, executive change, M&A, impairment, or other discrete event type). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and is clearly material to investors assessing the company's pipeline advancement and near-term catalysts.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-18
EX-99.1
This press release discloses the results of an Extraordinary General Meeting of Shareholders held on June 17, 2026. Shareholders voted in favor of all resolutions, including approval of share cancellation from a buyback program and amendments to the articles of association regarding board indemnification and shareholder meeting procedures. The disclosure of shareholder vote results is a material governance event that affects the registrant's capital structure and governance framework.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 7.01
Graham Corporation disclosed slides for its 2026 Investor Day presentation posted to its investor relations website on June 18, 2026, furnished under Item 7.01 (Regulation FD Disclosure). The presentation includes forward-looking guidance on 3-year targets (8-10% incremental margin expansion, >14% organic revenue CAGR, selective M&A, and top-quartile enterprise ROIC through FY27-FY29), strategic initiatives, and detailed business segment performance. While Regulation FD disclosures are typically routine, this presentation contains material forward-looking financial targets and strategic guidance that would affect a reasonable investor's assessment of the company's growth trajectory and capital allocation plans, warranting classification as a material event that does not fit the more specific categories.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-18
Item 5.02
Brian C. White was elected to Allegro Microsystems' Board of Directors as a Class III Director effective June 17, 2026, and appointed to the Audit Committee and Compensation Committee. White brings over 30 years of semiconductor industry experience and prior CFO roles at major public companies including Ambarella, Maxim Integrated, and IDT.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-18
EX-99.1
Navigator Gas announces entry into financing arrangements totaling $205.8 million for two newbuild vessels: a $164.64 million pre-delivery bridge facility with BNP Paribas and a $205.8 million long-term JOLCO (Japanese Operating Lease with Call Option) sale-leaseback arrangement. These represent creation of new direct financial obligations material to the company's capital structure and funding strategy for its fleet expansion.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
Atmos Energy entered into an underwriting agreement on June 15, 2026 to issue $700 million in 4.750% Senior Notes due 2032 in a registered public offering, with expected net proceeds of approximately $693.9 million. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial position, it does not fit cleanly into the more specific event categories (it is not M&A activity, a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive equity issuance, or litigation). The disclosure is a straightforward debt financing announcement properly classified as other material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
Broadcom announced the pricing, expiration, and results of cash tender offers for approximately $2.9 billion in outstanding debt securities, with an upsize of the consideration cap from $2.5 billion to $3.0 billion. While this is a material capital structure transaction affecting the company's debt profile, it does not fit neatly into the standard M&A taxonomy (ma_activity typically covers acquisitions, dispositions, mergers, or changes of control). The tender offer is a debt refinancing/repurchase activity that would materially affect investor assessment of the company's financial position and leverage, but lacks a dedicated 8-K event type.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Dr. Michael Cuffe, Executive Vice President and Chief Clinical Officer, is stepping down effective August 31, 2026, with a transitional role through February 2027. This is a departure of a named executive officer from a senior leadership position. While severance benefits are mentioned, the principal disclosed action is the departure itself, making this an exec_departure event rather than exec_compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-18
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of an annual meeting of stockholders held on June 16, 2026. The filing presents voting results for four proposals: election of directors (Proposal 1), ratification of auditor MaloneBailey, LLP (Proposal 2), approval of warrant issuance exceeding 19.99% of outstanding shares under Nasdaq Rule 5635(d) (Proposal 3), and approval of a reverse stock split amendment (Proposal 4). The disclosure is material because the warrant approval and reverse stock split authorization represent significant corporate actions affecting shareholder equity and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
The filing discloses an unregistered sale of $40 million in common shares pursuant to capital call notices delivered to investors under subscription agreements, relying on Section 4(a)(2), Regulation D, and/or Regulation S exemptions. This is a classic dilutive private placement that would materially affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Going Concern
confidence 95%
filed 2026-06-18
Item 2.02
The filing explicitly discloses "substantial doubt about the Trust's ability to continue as a going concern" due to insufficient cash reserves, no distributions since July 2023, and accumulated excess costs totaling $28.95 million across three conveyances. The Trustee states the Trust "may have to take drastic measures to continue to exist or alternatively may have to terminate," and is reviewing options including potential asset sales or termination, which would require 80% unitholder approval. This is a material going-concern disclosure that would significantly affect investor assessment of the Trust's viability.
View raw filing on EDGAR →
6-K
Material Impairment
confidence 95%
filed 2026-06-18
BHP discloses an expected impairment charge of approximately US$2.3 billion related to its Jansen potash project investment, driven by higher forecast capital intensity. The company states: "we currently expect to recognise an impairment charge of approximately US$2.3 billion (before and after tax) in relation to our investment to date in the Jansen project." This is a material write-down of asset value triggered by revised project economics and cost escalation.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-06-18
Item 2.02
The filing discloses the Trust's monthly cash distribution of $0.024673 per unit and provides detailed financial results for May 2026, including production volumes, pricing, revenues, and net profits from underlying properties. This is a routine monthly earnings/distribution announcement typical of royalty trusts, disclosed via press release under Item 2.02. While the filing also mentions a proposed business combination (SoftVest proposal), the primary disclosed action is the financial results and distribution announcement.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-18
The 6-K furnishes a press release announcing the appointment of David Hammarwall as Head of Business Area Networks and Senior Vice President, effective October 1, 2026, with membership on Ericsson's Executive Team reporting to the CEO. This is a material executive appointment to a senior leadership position within the registrant's organizational structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
This disclosure reports the Company's Net Asset Value (NAV) per share as of May 31, 2026, across six classes of common shares and OP Units, calculated in accordance with board-approved valuation guidelines. For a non-traded REIT, NAV per share is a critical metric for investor valuation and redemption pricing, making this material to shareholders. However, it does not fit neatly into the more specific event categories (e.g., earnings_release, which typically involves P&L results rather than NAV-only disclosures), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-18
Item 2.02
PermRock Royalty Trust issued a press release on June 18, 2026 announcing monthly financial results, including cash distribution amounts ($370,879.54 total, $0.030485 per unit), underlying oil and natural gas sales volumes, average wellhead prices, and detailed breakdowns of cash receipts, operating expenses, and taxes for the current and prior months. This is a periodic financial results disclosure typical of earnings releases, filed under Item 2.02 and furnished as Exhibit 99.1, and is material to unitholders assessing the Trust's cash generation and distribution capacity.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
This disclosure reports the Company's Net Asset Value (NAV) per share as of May 31, 2026, broken down by share class, along with detailed components of NAV and month-over-month comparison to April 30, 2026. For a non-traded REIT, NAV per share is a critical valuation metric that directly affects investor pricing and redemption decisions. While this is a routine monthly NAV disclosure typical of non-traded REITs, it is material to investors assessing the registrant's value and performance. The event does not fit neatly into more specific categories (not earnings, not an impairment, not a going-concern issue), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder vote results from Blue Ridge Bankshares' June 17, 2026 Annual Meeting of Shareholders. The filing reports voting outcomes for two proposals: (1) election of five directors (Heather M. Cozart, Harry Golliday, Otis S. Jones, Anthony R. Scavuzzo, and William W. Stokes), and (2) ratification of Elliott Davis, PLLC as independent auditor. All directors were elected with substantial majorities, and the auditor ratification passed overwhelmingly. This is a material disclosure as it documents the composition of the board and auditor approval, both of which affect investor assessment of governance and financial oversight.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-18
Item 2.02
This is a monthly cash distribution announcement by a royalty trust, which is the functional equivalent of an earnings release for this type of entity. The news release discloses the distribution amount ($0.044186 per unit), payment date, and underlying operational metrics (oil and gas sales volumes and average prices), along with excess cost information. For a trust whose primary purpose is distributing cash to unitholders, this disclosure is material to investors assessing the trust's cash generation and distribution capacity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 3.02
AB Private Lending Fund completed an unregistered sale of 2,060 Class I common shares of beneficial interest to feeder vehicles, exempt under Section 4(a)(2) and Regulation S, materially affecting the capital structure and ownership interests of existing shareholders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-18
Item 2.02
The filing discloses the Trust's financial results for April 2026 production, including revenue ($3,023,335), production costs ($3,797,936), gas volumes, and pricing data. The press release announces no monthly cash distribution due to excess production costs ($9,258,749 gross cumulative deficit) and low natural gas pricing. This is a material disclosure of operational and financial condition results typical of Item 2.02 earnings releases, though the primary news is the suspension of distributions rather than positive earnings.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
NVIDIA completed a $24.5 billion debt offering across seven tranches of senior notes with maturities from 2028 to 2056. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit cleanly into the standard 8-K taxonomy—it is neither a dilutive equity issuance (Item 3.02) nor a covenant breach or going-concern disclosure. The disclosure is routine debt issuance documentation filed under Item 8.01 (Other Events), making "other_material" the most appropriate classification for this significant but structurally standard debt capital raise.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This Item 5.07 disclosure reports the results of T-Mobile's Annual Meeting of Stockholders held on June 16, 2026, including voting outcomes for three proposals: election of 13 directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core content, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-18
Item 1.01
Silvercrest entered into a Second Amendment to its credit agreement with City National Bank, extending the term loan maturity to June 18, 2029 and establishing a $5.0 million term loan commitment plus a $10.0 million revolving facility. This amendment creates a direct financial obligation affecting the company's capital structure and debt obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Ouster held its 2026 Annual Meeting of Stockholders on June 17, 2026, with shareholders voting on five proposals: election of two Class II directors (Phillip M. Eyler and Angus Pacala), ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, amendment to increase authorized common shares from 100 million to 200 million, and amendment regarding officer exculpation. Four of the five proposals passed, with the officer exculpation amendment failing.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This Item 5.07 filing discloses the results of Mirum Pharmaceuticals' 2026 Annual Meeting of Stockholders held on June 15, 2026, including voting outcomes for three proposals: election of three Class I directors (Lon Cardon, William Fairey, and Timothy Walbert), ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation. The detailed vote tallies for each proposal are the core disclosure, making this a textbook shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of OPKO Health's 2026 Annual Meeting of Stockholders held on June 18, 2026. The filing presents voting results for four proposals: election of eleven directors, approval of the 2026 Equity Incentive Plan, advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-18
Item 5.07
This Item 5.07 filing discloses the results of Guardant Health's annual stockholder meeting held on June 17, 2026, including voting outcomes on four proposals: director elections (Proposal 1), auditor ratification (Proposal 2), say-on-pay advisory vote (Proposal 3), and frequency of future say-on-pay votes (Proposal 4). The filing presents detailed vote tallies for each proposal, which is the core disclosure required under Item 5.07. Notably, Proposal 3 (compensation advisory vote) was not approved, which is material information for investors assessing executive compensation governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This Item 5.07 disclosure reports the results of Block, Inc.'s 2026 annual meeting of stockholders held on June 16, 2026, including voting outcomes on four proposals: election of four Class II directors (all elected), advisory approval of named executive officer compensation (approved), ratification of Ernst & Young LLP as independent auditor (approved), and a stockholder proposal to establish a board-level technology committee (not approved). The detailed vote tallies and quorum information are characteristic of shareholder vote results disclosures required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder vote results from Corsair Gaming's 2026 Annual Meeting held on June 16, 2026. The filing reports voting outcomes for two proposals: (1) election of Class III director nominees Thi L. La and Randall J. Weisenburger, and (2) ratification of KPMG LLP as independent auditor. Both proposals passed with substantial majorities. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Agios Pharmaceuticals held its Annual Meeting of Stockholders, at which stockholders elected Class I directors (Rahul Ballal, Brian Goff, Cynthia Smith), approved an advisory vote on named executive officer compensation, approved an amendment to the 2023 Stock Incentive Plan increasing the share reserve by 2,000,000 shares, and ratified PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-18
Item 1.01
Seadrill entered into Amendment No. 2 to its Senior Secured Revolving Credit Agreement on June 16, 2026, increasing commitments from $225 million to $300 million, extending maturity from 2028 to 2031, and amending restrictive covenants for greater operational flexibility. This material modification to the company's capital structure and financing arrangements affects liquidity and financial flexibility.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from Xometry's 2026 Annual Meeting held on June 16, 2026, filed under Item 5.07. The filing reports final voting tallies for three proposals: election of three Class II directors (Roy Azevedo, Fabio Rosati, and Katharine Weymouth), advisory approval of named executive officer compensation, and ratification of Deloitte and Touche LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 1.01
Whirlpool entered into a First Supplemental Indenture on June 18, 2026, amending the indenture governing its 1.100% Notes due 2027 to accelerate the satisfaction and discharge timeline from one year to two years. This material amendment affects the company's debt obligations and refinancing flexibility.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 8.01
The board of directors declared a quarterly distribution of $0.25 per share ($1.00 annualized) for American Healthcare REIT shareholders. This distribution declaration is material to investors as it affects shareholder returns and capital allocation expectations, though it does not fit the more specific 8-K event categories.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Stockholders voted at the June 16, 2026 Annual Meeting on four proposals: election of Class I directors (Herring, Kidd, Rudow), ratification of RSM US LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the 2026 Equity Incentive Plan. All proposals received shareholder approval with tabulated voting results disclosed.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Andrew C. Carington departed Hamilton Beach Brands as Senior Vice President, General Counsel and Secretary, effective immediately on June 18, 2026. The departure of a senior executive holding the General Counsel position—a key officer responsible for legal and governance matters—is material to investors' assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-18
Item 5.02
Sean Rowles was appointed as Chief Risk Officer effective June 17, 2026, to lead Oportun's risk and credit functions, succeeding Patrick Kirscht who departed after 18 years in the Chief Credit Officer role.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-18
Item 1.01
Universal Insurance Holdings entered into Note Purchase Agreements on June 16, 2026, to issue and sell $100 million of 7.75% Senior Unsecured Notes due 2031 in a private placement. The company used proceeds to redeem all outstanding 2026 Notes on June 17, 2026, at par plus accrued interest, representing a material refinancing and capital structure transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Standard Biotools held its Annual Meeting of Stockholders on April 24, 2026, with stockholders voting on five proposals: election of three Class I directors (Michael Egholm, Thomas Carey, and Eli Casdin), advisory approval of executive compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of the 2026 Equity Incentive Plan, and approval of an amendment to the 2017 Employee Stock Purchase Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from PJT Partners' 2026 Annual Meeting held on June 18, 2026. The filing presents final vote tallies for three proposals: director elections (K. Don Cornwell, Peter L.S. Currie, Thomas M. Ryan), advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material governance disclosure that investors rely upon to confirm board composition and audit firm appointment.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-06-18
EX-99.1
This exhibit is a notice of partial redemption of US$165 million of Studio City Finance Limited's US$500 million 6.500% Senior Notes due 2028. While technically a redemption (retirement) of existing debt rather than issuance of new debt, it represents a material modification of the registrant's direct financial obligations and capital structure. The redemption on July 18, 2026 at par plus accrued interest is a significant financial event affecting debt outstanding. This is classified as debt_issuance under the broader category of "creation of a new direct financial obligation" or material debt activity, though a redemption is technically the inverse; the closest fit is debt_issuance as it involves a material debt transaction, though financial_other could also apply.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from SAB Biotherapeutics' 2026 Annual Meeting of Stockholders held on June 18, 2026. The filing reports the outcomes of two proposals: (1) election of four Class II directors (David Zaccardelli, David Link, Katie Ellias, and Andrew Moin) with detailed vote tallies, and (2) ratification of EisnerAmper LLP as independent auditor. The disclosure includes quorum information (76.12% attendance) and complete voting results for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-18
Item 8.01
BCB Bancorp's Board voted to suspend quarterly cash dividends on common and preferred stock and suspend its dividend reinvestment plan, citing the need for capital preservation during a "fulsome evaluation of the Bank's credit portfolios." The CEO explicitly states this decision is to preserve the Bank's "well-capitalized" position, signaling underlying credit or capital concerns. While dividend suspension is material to investors, it does not fit neatly into the more specific event categories (not a restatement, going-concern disclosure, covenant breach, or impairment charge), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder vote results from a special meeting held on June 18, 2026. The filing reports the final voting tallies on Proposal 1 authorizing the Company to issue common stock below net asset value (NAV), with detailed vote counts for and against. This authorization to issue dilutive equity is material to investors as it affects potential share dilution and the Company's capital structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-18
Item 5.02
Caroline Tsai, Chief Legal & Corporate Affairs Officer and Corporate Secretary, is stepping down effective July 1, 2026. While the filing also discloses Chip Keller's appointment as Chief Legal Officer, the primary disclosed action centers on Ms. Tsai's departure after four years with the company. The filing emphasizes her role in major transactions (Worldpay divestiture and TSYS acquisition), making her departure material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-18
Item 5.07
Contango held its 2026 Annual Meeting of Stockholders on June 18, 2026, at which all seven director nominees were elected, Baker Tilly US, LLP was ratified as auditor, and non-binding advisory votes on executive compensation and say-on-pay frequency (annual) were approved.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-18
Item 5.02
Vishwas Setia's separation as Chief Financial Officer is the primary disclosed action, effective immediately following an HR violation review. While Jonathan Gillis's appointment as interim CFO is also disclosed, the filing centers on Setia's departure and the circumstances surrounding it (separation agreement, COBRA coverage). The CFO role is a named executive officer position material to investors' assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-18
Item 1.01
Atmos Energy completed a $700 million public offering of senior notes on June 18, 2026, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 encompasses material definitive agreements including significant financing activities. The $693.9 million in net proceeds represents a material capital transaction that would affect investor assessment of the company's financial position and capital structure. However, this is more accurately characterized as a material financing event than M&A activity proper.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 1.01
Faeth Therapeutics entered into an at-the-market (ATM) offering agreement with TD Securities on June 18, 2026, authorizing the sale of up to $150 million in common stock shares, representing a classic dilutive equity issuance that signals potential capital needs and future shareholder dilution.
View raw filing on EDGAR →